All In MedTech

Device Trial Radar · NCT03583957

A Wireless EEG Patch for Continuous Electrographic Monitoring

Last checked: Nov 20, 2026Latest source record: Feb 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

750

Planned (sponsor's estimate)

Start

May 8, 2018

Primary completion

Apr 30, 2026

Study completion Apr 30, 2026

Sponsor

Lead sponsor
Epitel, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Boston Children's Hospital; National Institute of Neurological Disorders and Stroke (NINDS); NYU Langone Health; University of Colorado, Denver
First posted
Jul 12, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This proposal will evaluate an individual-use, patch-type telemetry device for simplified, single-channel EEG recording from human patients along-side the traditional in hospital wired EEG.

Conditions

  • Epilepsy

Interventions

  • Observational onlyDevice

    Device is only observational and used to record EEG.

  • Psychological and Behavioral interaction with a seizure forecasting mobile appBehavioral

    Participants will be interacting with a mobile app to input perceived behavioral (e.g., number of hours slept and sleepiness) and psychological (perceived stress).

  • Seizure Alerting and Prediction SystemCombination product

    The combination of Epilog (device) and the Aura app (psychological and behavioral interaction) will be used to create a real-time seizure alerting and an hourly seizure forecasting system.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Single channel EEG coherenceTime frame: Through study completion
  2. Sensitivity and specificity for retrospect seizure detectionTime frame: Through Phase I completion, 2 years
  3. Sensitivity and specificity for prospective seizure alertingTime frame: Through study completion, 5 years

1 more outcomes with a free account

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Colorado Anschutz Medical Center

    Aurora, Colorado

  • Boston Children's Hospital

    Boston, Massachusetts

  • New York University Langone Medical Center

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.